Flosonics Medical Secures $20 Million in Series C Funding
March 21, 2024, 9:34 pm
Location: Canada, Ontario, Toronto
Employees: 51-200
Founded date: 2015
Total raised: $39M
Flosonics Medical, a pioneer in wearable medical ultrasound technology, has successfully raised $20 million in a Series C funding round. The funding was spearheaded by New Leaf Venture Partners, along with support from existing investors Arboretum Ventures, Genesys Capital, and iGan Partners.
This latest injection of capital will fuel Flosonics Medical's ongoing efforts to innovate and drive the adoption of their groundbreaking FloPatch device, a wearable Doppler ultrasound designed for hemodynamic assessments. The company is on a mission to revolutionize patient care by providing AI-assisted sensors that can enhance patient management both in and out of the hospital setting.
Vijay Lathi, a seasoned MedTech investor known for his expertise in data convergence and guiding growth-stage companies, will be joining Flosonics Medical's board of directors. This strategic partnership is expected to further propel the company's growth and expansion plans.
CEO Joe Eibl expressed his excitement about the Series C funding round, highlighting the opportunity it presents for Flosonics Medical to elevate the standard of care for critically ill patients and expand into new markets. The investment from New Leaf Venture Partners underscores the significant impact that Flosonics Medical's technology is poised to have on the healthcare industry.
With a focus on innovation and evidence generation, Flosonics Medical is well-positioned to utilize the Series C funding to accelerate commercial growth, broaden the applications of their technology, and continue to make strides in improving patient outcomes. The company's commitment to excellence and dedication to advancing medical technology make them a key player in the evolving landscape of wearable ultrasound devices.
As Flosonics Medical continues to push the boundaries of medical innovation, the future looks bright for this trailblazing company at the forefront of wearable medical ultrasound technology.
This latest injection of capital will fuel Flosonics Medical's ongoing efforts to innovate and drive the adoption of their groundbreaking FloPatch device, a wearable Doppler ultrasound designed for hemodynamic assessments. The company is on a mission to revolutionize patient care by providing AI-assisted sensors that can enhance patient management both in and out of the hospital setting.
Vijay Lathi, a seasoned MedTech investor known for his expertise in data convergence and guiding growth-stage companies, will be joining Flosonics Medical's board of directors. This strategic partnership is expected to further propel the company's growth and expansion plans.
CEO Joe Eibl expressed his excitement about the Series C funding round, highlighting the opportunity it presents for Flosonics Medical to elevate the standard of care for critically ill patients and expand into new markets. The investment from New Leaf Venture Partners underscores the significant impact that Flosonics Medical's technology is poised to have on the healthcare industry.
With a focus on innovation and evidence generation, Flosonics Medical is well-positioned to utilize the Series C funding to accelerate commercial growth, broaden the applications of their technology, and continue to make strides in improving patient outcomes. The company's commitment to excellence and dedication to advancing medical technology make them a key player in the evolving landscape of wearable ultrasound devices.
As Flosonics Medical continues to push the boundaries of medical innovation, the future looks bright for this trailblazing company at the forefront of wearable medical ultrasound technology.